Port Delivery System implant is noninferior to intravitreal ranibizumab for neovascular AMD

• Posted on: Mar 3 2022
• By: Saratoga Opthalmology
• Leave a response

Results from Archway, a phase 3 trial that assessed the Port Delivery System vs. intravitreal ranibizumab, showed that the implant was noninferior and offered equivalent efficacy to monthly injections.
Source: AAO

Posted in: Uncategorized